In an effort to shake up an organization [1] that has produced few major advances recently, GlaxoSmithKline announced plans to axe 350 jobs in its R&D operations. The cuts--part of a major restructuring [1] announced last fall--will terminate staffers at three labs in the U.S., Italy and Germany. These layoffs reflect the CEO Andrew Witty's [1] strategic move to look outside the company for innovations in drug technology. Report [2]